首页 > 最新文献

Pharmaceutical patent analyst最新文献

英文 中文
Patent highlights December 2022-January 2023. 专利亮点2022年12月至2023年1月。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-07-01 Epub Date: 2023-10-06 DOI: 10.4155/ppa-2023-0016
Hermann Am Mucke
{"title":"Patent highlights December 2022-January 2023.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2023-0016","DOIUrl":"10.4155/ppa-2023-0016","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41149760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent patent-based review on the role of three-dimensional printing technology in pharmaceutical and biomedical applications. 关于三维打印技术在制药和生物医学应用中的作用的最新专利综述。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-07-01 Epub Date: 2023-10-26 DOI: 10.4155/ppa-2023-0018
Palak Rani, Vikas Yadav, Parijat Pandey, Kiran Yadav

Three-dimensional printing (3DP) is emerging as an innovative manufacturing technology for biomedical and pharmaceutical applications, since the US FDA approval of Spritam as a 3D-printed drug. In the present review, we have highlighted the potential benefits of 3DP technology in healthcare, such as the ability to create patient-specific medical devices and implants, as well as the possibility of on-demand production of drugs and personalized dosage forms. We have further discussed future research to optimize 3DP processes and materials for pharmaceutical and biomedical applications. Cohesively, we have put forward the current state of active patents and applications related to 3DP technology in the healthcare and pharmaceutical industries including hearing aids, prostheses, medical devices and drug-delivery systems.

自从美国食品药品监督管理局批准Spritam作为3D打印药物以来,三维打印(3DP)正成为生物医学和制药应用的一种创新制造技术。在本综述中,我们强调了3DP技术在医疗保健中的潜在优势,例如创建患者专用医疗设备和植入物的能力,以及按需生产药物和个性化剂型的可能性。我们进一步讨论了未来优化3DP工艺和材料用于制药和生物医学应用的研究。我们共同提出了3DP技术在医疗保健和制药行业的活跃专利和应用现状,包括助听器、假肢、医疗器械和药物输送系统。
{"title":"Recent patent-based review on the role of three-dimensional printing technology in pharmaceutical and biomedical applications.","authors":"Palak Rani, Vikas Yadav, Parijat Pandey, Kiran Yadav","doi":"10.4155/ppa-2023-0018","DOIUrl":"10.4155/ppa-2023-0018","url":null,"abstract":"<p><p>Three-dimensional printing (3DP) is emerging as an innovative manufacturing technology for biomedical and pharmaceutical applications, since the US FDA approval of Spritam as a 3D-printed drug. In the present review, we have highlighted the potential benefits of 3DP technology in healthcare, such as the ability to create patient-specific medical devices and implants, as well as the possibility of on-demand production of drugs and personalized dosage forms. We have further discussed future research to optimize 3DP processes and materials for pharmaceutical and biomedical applications. Cohesively, we have put forward the current state of active patents and applications related to 3DP technology in the healthcare and pharmaceutical industries including hearing aids, prostheses, medical devices and drug-delivery systems.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50162460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic charisma of imidazo [2,1-b] [1,3,4]-thiadiazole analogues: a patent review. 咪唑 [2,1-b] [1,3,4]- 噻二唑类似物的治疗魅力:专利回顾。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-07-01 Epub Date: 2023-09-06 DOI: 10.4155/ppa-2023-0006
Anuradha Mehra, Rekha Sangwan, Aryan Mehra, Shivani Sharma, Pankaj Wadhwa, Amit Mittal

Imidazothiadiazole was discovered around the 1950s era, containing an imidazole ring fused to a thiadiazole ring. Imidazothiadiazole exhibit versatile pharmacological properties including anticonvulsant, cardiotonic, anti-inflammatory, diuretic, antifungal, antibacterial and anticancer. Despite of the being discovered in 1950s, the imidazothiadiazole derivatives are unable to being processed to clinical trials because of lack of bioavailability, efficacy and cytotoxicity. The recent patent literature focused on structural modification of imidazothiadiazole core to overcome these problems. This review limelight a disease-centric perspective on patented imidazothiadiazole from 2015-2023 and to understand their mechanism of action in related diseases. The relevant granted patent applications were located using patent databases, Google Patents, USPTO, EPO, WIPO, Espacenet and Lens.

咪唑噻二唑是在 20 世纪 50 年代左右发现的,含有一个咪唑环和一个噻二唑环。咪唑噻二唑具有抗惊厥、强心、消炎、利尿、抗真菌、抗菌和抗癌等多种药理特性。尽管咪唑噻二唑衍生物早在 20 世纪 50 年代就已被发现,但由于缺乏生物利用度、药效和细胞毒性,一直未能进入临床试验阶段。最近的专利文献主要集中在对咪唑噻二唑核心进行结构改造,以克服这些问题。本综述从疾病为中心的角度对2015-2023年的咪唑噻二唑专利进行分析,并了解其在相关疾病中的作用机制。相关已授权专利申请是通过专利数据库、谷歌专利、美国专利商标局、欧洲专利局、世界知识产权组织、Espacenet 和 Lens 查找的。
{"title":"Therapeutic charisma of imidazo [2,1-b] [1,3,4]-thiadiazole analogues: a patent review.","authors":"Anuradha Mehra, Rekha Sangwan, Aryan Mehra, Shivani Sharma, Pankaj Wadhwa, Amit Mittal","doi":"10.4155/ppa-2023-0006","DOIUrl":"10.4155/ppa-2023-0006","url":null,"abstract":"<p><p>Imidazothiadiazole was discovered around the 1950s era, containing an imidazole ring fused to a thiadiazole ring. Imidazothiadiazole exhibit versatile pharmacological properties including anticonvulsant, cardiotonic, anti-inflammatory, diuretic, antifungal, antibacterial and anticancer. Despite of the being discovered in 1950s, the imidazothiadiazole derivatives are unable to being processed to clinical trials because of lack of bioavailability, efficacy and cytotoxicity. The recent patent literature focused on structural modification of imidazothiadiazole core to overcome these problems. This review limelight a disease-centric perspective on patented imidazothiadiazole from 2015-2023 and to understand their mechanism of action in related diseases. The relevant granted patent applications were located using patent databases, Google Patents, USPTO, EPO, WIPO, Espacenet and Lens.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10164946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent landscape of platelet growth factor receptor and c-KIT targets. 血小板生长因子受体和c-KIT靶点的专利前景。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-07-01 Epub Date: 2023-09-27 DOI: 10.4155/ppa-2023-0005
Hai-Long Zhang, Qian Kong

Type III receptor tyrosine kinase, e.g., PDGFR, are associated with various autoimmune diseases. To show the status of PDGFR and c-KIT targets, we performed the US patent analysis. The present study showed that the R&D of c-KIT target was much earlier than the R&D of PDGFR targets. Currently, the PDGFR-based target demonstrates more applications in the development of biological therapy. Our findings indicated that some inhibitors of c-KIT target contained sulfur elements or 1,3-diazine rings. The c-KIT target has more competitive edges for chemical drug discovery than the PDGFR target. c-KIT and PDGFR targets are currently preferable for drug discovery in autoimmune diseases. This study was the first to show R&D differentiation between PDGFR and c-KIT targets in drug development.

III型受体酪氨酸激酶,例如PDGFR,与各种自身免疫性疾病有关。为了显示PDGFR和c-KIT靶点的状态,我们进行了美国专利分析。本研究表明,c-KIT靶点的研发远早于PDGFR靶点的开发。目前,基于PDGFR的靶点在生物治疗的发展中有更多的应用。我们的研究结果表明,一些c-KIT靶向抑制剂含有硫元素或1,3-二嗪环。c-KIT靶点在化学药物发现方面比PDGFR靶点更有竞争力。c-KIT和PDGFR靶点目前优选用于自身免疫性疾病中的药物发现。这项研究首次表明PDGFR和c-KIT靶点在药物开发中的研发差异。
{"title":"Patent landscape of platelet growth factor receptor and c-KIT targets.","authors":"Hai-Long Zhang, Qian Kong","doi":"10.4155/ppa-2023-0005","DOIUrl":"10.4155/ppa-2023-0005","url":null,"abstract":"<p><p>Type III receptor tyrosine kinase, e.g., PDGFR, are associated with various autoimmune diseases. To show the status of PDGFR and c-KIT targets, we performed the US patent analysis. The present study showed that the R&D of c-KIT target was much earlier than the R&D of PDGFR targets. Currently, the PDGFR-based target demonstrates more applications in the development of biological therapy. Our findings indicated that some inhibitors of c-KIT target contained sulfur elements or 1,3-diazine rings. The c-KIT target has more competitive edges for chemical drug discovery than the PDGFR target. c-KIT and PDGFR targets are currently preferable for drug discovery in autoimmune diseases. This study was the first to show R&D differentiation between PDGFR and c-KIT targets in drug development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41139705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug repurposing of mito-atovaquone for cancer treatment. Mito-Atovaquone用于癌症治疗的药物再利用。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-07-01 Epub Date: 2023-10-06 DOI: 10.4155/ppa-2023-0015
Nemesio Villa-Ruano, Maricruz Anaya-Ruiz, Luis Villafaña-Diaz, Diana Barron-Villaverde, Martin Perez-Santos

Repurposing of approved drugs in a new strategy to combat cancer that leads to savings in time and investment. Atovaquone is a US FDA-approved drug for treatment of Pneumocystis carinii pneumonia and malaria. Patent US2023017373 describe the use of mito-atovaquone for the treatment of several types of cancer. Mito-atovaquone demonstrated antiproliferative activity in cell lines of pancreatic cancer, lung cancer and brain cancer and inhibited tumor growth in syngeneic mouse models and in animals genetically prone to breast cancer. Mito-atovaquone has the potential to be used successfully in the treatment of various types of tumors.

在抗击癌症的新战略中重新利用已批准的药物,从而节省时间和投资。阿托伐醌是美国食品药品监督管理局批准的治疗卡氏肺孢子虫肺炎和疟疾的药物。专利US2023017373描述了mito-atovaquone用于治疗几种类型的癌症的用途。Mito-Atovaquone在胰腺癌症、癌症和脑癌症的细胞系中表现出抗增殖活性,并在同基因小鼠模型和遗传上易患癌症的动物中抑制肿瘤生长。Mito-Atovaquone有潜力成功用于治疗各种类型的肿瘤。
{"title":"Drug repurposing of mito-atovaquone for cancer treatment.","authors":"Nemesio Villa-Ruano, Maricruz Anaya-Ruiz, Luis Villafaña-Diaz, Diana Barron-Villaverde, Martin Perez-Santos","doi":"10.4155/ppa-2023-0015","DOIUrl":"10.4155/ppa-2023-0015","url":null,"abstract":"<p><p>Repurposing of approved drugs in a new strategy to combat cancer that leads to savings in time and investment. Atovaquone is a US FDA-approved drug for treatment of <i>Pneumocystis carinii</i> pneumonia and malaria. Patent US2023017373 describe the use of mito-atovaquone for the treatment of several types of cancer. Mito-atovaquone demonstrated antiproliferative activity in cell lines of pancreatic cancer, lung cancer and brain cancer and inhibited tumor growth in syngeneic mouse models and in animals genetically prone to breast cancer. Mito-atovaquone has the potential to be used successfully in the treatment of various types of tumors.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41144212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent profile for the approved and in clinical trials Mpox vaccines. 已批准和正在进行临床试验的猴痘疫苗的专利简介。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-05-01 Epub Date: 2023-09-06 DOI: 10.4155/ppa-2023-0017
Irene von der Weid, Cristina d'Urso de Souza Mendes, Paula C Fonseca, Sandro G Viveiros Rosa

Mpox disease was reported in 110 countries since May 2022, with 88,026 cases and 148 deaths by 21 June 2023. Although some drugs were already approved for Mpox treatment, the available smallpox vaccines can provide 85% cross-prevention, but there are no scientific publications describing the patent portfolio for Mpox vaccines. This paper aims to contribute to the identification of the status of the smallpox vaccine patents now applied for Mpox. We retrieved ten vaccines, but only a few had a patent portfolio and one under patent litigation processes in three continents. Also, no specific Mpox vaccine was retrieved and, in this sense, technological monitoring studies should be performed to provide a future vision regarding Mpox prophylaxis.

自2022年5月以来,110个国家报告了猴痘病,截至2023年6月21日,已有88026例病例和148例死亡。尽管一些药物已经被批准用于猴痘治疗,但现有的天花疫苗可以提供85%的交叉预防,但没有科学出版物描述猴痘疫苗的专利组合。本文旨在为查明猴痘目前申请的天花疫苗专利状况做出贡献。我们检索到了十种疫苗,但只有少数疫苗拥有专利组合,其中一种正在三大洲的专利诉讼程序中。此外,没有检索到特定的猴痘疫苗,从这个意义上说,应该进行技术监测研究,以提供猴痘预防的未来愿景。
{"title":"Patent profile for the approved and in clinical trials Mpox vaccines.","authors":"Irene von der Weid, Cristina d'Urso de Souza Mendes, Paula C Fonseca, Sandro G Viveiros Rosa","doi":"10.4155/ppa-2023-0017","DOIUrl":"10.4155/ppa-2023-0017","url":null,"abstract":"<p><p>Mpox disease was reported in 110 countries since May 2022, with 88,026 cases and 148 deaths by 21 June 2023. Although some drugs were already approved for Mpox treatment, the available smallpox vaccines can provide 85% cross-prevention, but there are no scientific publications describing the patent portfolio for Mpox vaccines. This paper aims to contribute to the identification of the status of the smallpox vaccine patents now applied for Mpox. We retrieved ten vaccines, but only a few had a patent portfolio and one under patent litigation processes in three continents. Also, no specific Mpox vaccine was retrieved and, in this sense, technological monitoring studies should be performed to provide a future vision regarding Mpox prophylaxis.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10159780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights October-November 2022. 专利亮点2022年10月至11月。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-05-01 Epub Date: 2023-07-21 DOI: 10.4155/ppa-2023-0008
Hermann Am Mucke

A snapshot of recent noteworthy developments in the patent literature of relevance to pharmaceutical and medical research and development.

与药物和医学研发相关的专利文献中最近值得注意的发展的快照。
{"title":"Patent highlights October-November 2022.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2023-0008","DOIUrl":"10.4155/ppa-2023-0008","url":null,"abstract":"<p><p>A snapshot of recent noteworthy developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9844105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Morita-Baylis-Hillman adducts and their derivatives: a patent-based exploration of diverse biological activities. Morita-Baylis-Hillman加合物及其衍生物:对多种生物活性的专利探索。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-05-01 Epub Date: 2023-09-06 DOI: 10.4155/ppa-2023-0021
Ricardo S Porto, Viviane A Porto

Morita-Baylis-Hillman adducts are polyfunctionalized compounds that result from a three-component reaction involving an electrophilic sp2 carbon (aldehyde, ketone or imine) and the α-position of an activated alkene, catalyzed by a tertiary amine. These adducts exhibit a wide range of biological activities and act as valuable starting materials for developing drug candidates, pesticides, polymers, and other applications. In this regard, the present review aimed to explore the biological potential of Morita-Baylis-Hillman adducts and their derivatives as documented in patent literature. Additionally, the review delves into the synthetic methodologies employed in their preparation.

Morita-Baylis-Hillman加合物是由亲电sp2碳(醛、酮或亚胺)和活性烯烃的α-位在叔胺催化下的三组分反应产生的多官能化化合物。这些加合物表现出广泛的生物活性,是开发候选药物、杀虫剂、聚合物和其他应用的有价值的起始材料。在这方面,本综述旨在探索专利文献中记载的Morita-Baylis-Hillman加合物及其衍生物的生物学潜力。此外,该综述深入探讨了它们制备过程中使用的合成方法。
{"title":"Morita-Baylis-Hillman adducts and their derivatives: a patent-based exploration of diverse biological activities.","authors":"Ricardo S Porto,&nbsp;Viviane A Porto","doi":"10.4155/ppa-2023-0021","DOIUrl":"10.4155/ppa-2023-0021","url":null,"abstract":"<p><p>Morita-Baylis-Hillman adducts are polyfunctionalized compounds that result from a three-component reaction involving an electrophilic sp<sup>2</sup> carbon (aldehyde, ketone or imine) and the α-position of an activated alkene, catalyzed by a tertiary amine. These adducts exhibit a wide range of biological activities and act as valuable starting materials for developing drug candidates, pesticides, polymers, and other applications. In this regard, the present review aimed to explore the biological potential of Morita-Baylis-Hillman adducts and their derivatives as documented in patent literature. Additionally, the review delves into the synthetic methodologies employed in their preparation.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10159784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent analysis of novel therapeutic approaches for treating Alzheimer's disease 2018-2023. 治疗阿尔茨海默病的新型治疗方法专利分析2018-2023。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-05-01 Epub Date: 2023-07-21 DOI: 10.4155/ppa-2023-0020
Faiza Saleem, Fouzia Naz, Khalid M Khan
{"title":"Patent analysis of novel therapeutic approaches for treating Alzheimer's disease 2018-2023.","authors":"Faiza Saleem,&nbsp;Fouzia Naz,&nbsp;Khalid M Khan","doi":"10.4155/ppa-2023-0020","DOIUrl":"10.4155/ppa-2023-0020","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9844106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current landscape and future prospects of RET and ROS1 targets. RET和ROS1目标的现状和未来前景。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-05-01 Epub Date: 2023-09-06 DOI: 10.4155/ppa-2023-0011
Hai-Long Zhang, Qian Kong

RET and ROS1 are becoming key targets for targeted therapy. To show current landscape of ROS1 and RET targets, a patent analysis was performed. The present results indicated that inhibitor structures of ROS1 target demonstrated unique elements compared with inhibitor structures of RET or BRAF targets. Our study was the first time to uncover that a number of inhibitor structures of ROS1 target contained sulfur and boron elements. The inhibitors of RET target could be developed for treatment of various cancers, including lung cancer, thyroid cancer, and other solid tumor, while the inhibitors of ROS1 target are virtually developed for treatment of lung cancer. Our findings provide a new insight for drug discovery of ROS1 and RET target.

RET和ROS1正在成为靶向治疗的关键靶点。为了显示ROS1和RET靶点的现状,进行了专利分析。目前的结果表明,与RET或BRAF靶点的抑制剂结构相比,ROS1靶点的抑制结构表现出独特的元素。我们的研究首次发现ROS1靶的许多抑制剂结构含有硫和硼元素。RET靶点抑制剂可用于治疗各种癌症,包括肺癌癌症、癌症甲状腺癌和其他实体瘤,而ROS1靶点抑制剂实际上用于治疗癌症。我们的发现为ROS1和RET靶点的药物发现提供了新的见解。
{"title":"Current landscape and future prospects of RET and ROS1 targets.","authors":"Hai-Long Zhang,&nbsp;Qian Kong","doi":"10.4155/ppa-2023-0011","DOIUrl":"10.4155/ppa-2023-0011","url":null,"abstract":"<p><p>RET and ROS1 are becoming key targets for targeted therapy. To show current landscape of ROS1 and RET targets, a patent analysis was performed. The present results indicated that inhibitor structures of ROS1 target demonstrated unique elements compared with inhibitor structures of RET or BRAF targets. Our study was the first time to uncover that a number of inhibitor structures of ROS1 target contained sulfur and boron elements. The inhibitors of RET target could be developed for treatment of various cancers, including lung cancer, thyroid cancer, and other solid tumor, while the inhibitors of ROS1 target are virtually developed for treatment of lung cancer. Our findings provide a new insight for drug discovery of ROS1 and RET target.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10163336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pharmaceutical patent analyst
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1